 |
0 Diseases |  |
1 Trial |
|
1 Trial |  |
24 News |  |
- | purified human menopausal gonadotropin / Generic mfg., menotropin / Generic mfg.
Retrospective data, Journal: Effects of different gonadotropin preparations in GnRH antagonist protocol for patients with polycystic ovary syndrome during IVF/ICSI: a retrospective cohort study. (Pubmed Central) - Mar 2, 2024
For women with PCOS undergoing the GnRH antagonist protocol, the clinical pregnancy rates of fresh IVF/ICSI-ET cycle are similar for all four types of Gn. With a lower risk of OHSS and a similar number of high-quality and available embryos, HP-hMG may have an advantage in the PCOS population.
- | purified human menopausal gonadotropin / Generic mfg., menotropin / Generic mfg.
Retrospective data, Journal, HEOR, Cost-analysis: A direct healthcare cost analysis of recombinant LH versus hMG supplementation on FSH during controlled ovarian hyperstimulation in the GnRH-antagonist protocol. (Pubmed Central) - Jan 26, 2024
With a lower risk of OHSS and a similar number of high-quality and available embryos, HP-hMG may have an advantage in the PCOS population. The cost analysis showed that recombinant LH is more cost-effective than hMG supplementation on r-hFSH during COH in the GnRH-antagonist protocol.
- | Rekovelle (follitropin delta) / Ferring
Reimbursement, US reimbursement, Journal, HEOR: Highly Purified Human Menopausal Gonadotropin (HP-hMG) Versus Recombinant Follicle-Stimulating Hormone (rFSH) for Controlled Ovarian Stimulation in US (Pubmed Central) - Jul 22, 2023
Comparable clinical outcomes can be achieved at a lower cost when using HP-hMG versus rFSH based COS protocols in a cohort of predicted high-responders. Such cost savings may reduce the economic burden infertility currently presents to US healthcare providers and those seeking fertility care.
- | Menopur (menotropin) / Ferring
Journal: Analysis of Nurse and Patient Preferences for Pre-Filled Pen Devices for Self-Injection of Highly Purified Human Menopausal Gonadotropin (HP-hMG, MENOPUR). (Pubmed Central) - May 23, 2023
The prototype pen was perceived to possess the key attributes considered important for a gonadotropin pen by patients and nurses, including correcting the dose, the ability to self-inject safely and correctly, ease of preparation and use, and an injection which appeared to be as painless as possible. The prototype pen was found to perform well across all key attributes, especially those considered most important in gonadotropin pens, suggesting that it is a user-friendly option for patients undergoing ART.
- purified human menopausal gonadotropin / Generic mfg.
Impact of TROP-2 and its cellular localization on prognosis of breast cancer in the GAIN cohort (Exhibition area) - Mar 22, 2023 - Abstract #ESMOBC2023ESMO_BC_390;
P3
For mTROP-2, a product score (IRS) of grouped percentage and staining intensity showed better DFS and OS for IRS > 3 (also identified by Cutoff Finder) in HER2+/HRany and HER2+/HR+ patients (uni-/multivariate)...The results are relevant for biomarker strategies for future therapeutic concepts. In the SASCIA trial investigating Sacituzumab TROP-2 is prospectively assessed.
- || purified human menopausal gonadotropin / Generic mfg., menotropin / Generic mfg.
Observational data, Review, Journal, HEOR, Real-world evidence, Claims database, Real-world: Comparative effectiveness of gonadotropins used for ovarian stimulation during assisted reproductive technologies (ART) in France: A real-world observational study from the French nationwide claims database (SNDS). (Pubmed Central) - Jan 29, 2023
Using data from 245,534 stimulations (153,600 women), biosimilars resulted in a 19% lower live birth (adjusted odds ratio (OR) 0.81, 95% confidence interval (CI) 0.76-0.86) and a 14% lower cumulative live birth (adjusted hazard ratio (HR) 0.86, 95% CI 0.82-0.89); and HP-hMG resulted in a 7% lower live birth (adjusted OR 0.93, 95% CI 0.90-0.96) and an 11% lower cumulative live birth (adjusted HR 0.89, 95% CI 0.87-0.91) versus originator r-hFSH alfa. Results were consistent across strata (age and ART strategy), sensitivity analysis using propensity score matching, and with r-hFSH alfa and beta as the reference group.
- Ovidrel (choriogonadotropin alfa) / EMD Serono
Analytical investigation of the profile of human chorionic gonadotropin in highly purified human menopausal gonadotrophin preparations () - Jan 8, 2023 - Abstract #Fertility2023Fertility_338;
Objective: Highly-purified human menopausal gonadotropin (HP-hMG [Menopur, Ferring Pharmaceuticals, Switzerland]) contains 1:1 follicle-stimulating hormone (FSH) and luteinizing hormone (LH) activity...The reference was a mixture of r-hFSH/follitropin-alfa (GONAL-f), r-hLH/lutropin alfa [Luveris] and r-hCG (Ovidrel) (Merck KGaA, Darmstadt, Germany) constituted based on their reported activity (in IU) in the HP-hMG product label... Advanced molecular analysis of HP-hMG showed that the relative presence of hCG compared to LH may be higher than in the reference, and revealed absence of sulfated glycans, suggesting a mainly placental origin of hCG, with possible impact on receptor affinity/activation and clinical effect.
- | purified human menopausal gonadotropin / Generic mfg., menotropin / Generic mfg.
Observational data, Journal: Follitropin Alpha for assisted reproduction: an analysis based on a non-interventional study in Greece. (Pubmed Central) - Oct 5, 2022
The live birth rate, cost per oocyte, and the cost per live birth are in line with literature. OSI was a main contributing factor to the accurate prediction of the live birth rate, while age and BMI were found to be negatively correlated.
- | purified human menopausal gonadotropin / Generic mfg., menotropin / Generic mfg.
Journal: Consecutive versus concomitant follicle-stimulating hormone and highly purified human menopausal gonadotropin: A milder response but better quality. (Pubmed Central) - Jun 15, 2022
OSI was a main contributing factor to the accurate prediction of the live birth rate, while age and BMI were found to be negatively correlated. Personalized controlled ovarian stimulation using HP-hMG during the late follicular phase led to a significantly lower response, but did not affect the quality of ICSI.
- || purified human menopausal gonadotropin / Generic mfg., menotropin / Generic mfg.
Biomarker, Clinical, Journal: Added value of anti-Müllerian hormone serum concentration in assisted reproduction clinical practice using highly purified human menopausal gonadotropin (HP-hMG). (Pubmed Central) - Feb 9, 2022
Selecting the appropriate starting dose of gonadotropin is crucial to optimize the IVF/ICSI procedure. For the first attempt, the serum AMH level is a good biomarker to individualize treatment.
- || menotropin / Generic mfg.
Preclinical, Review, Journal: Successful live birth after in vitro maturation treatment in a patient with autoimmune premature ovarian failure: a case report and review of the literature. (Pubmed Central) - Feb 8, 2022
Management of reproductive age women with autoimmune pathology requires fertility counseling. Early diagnosis of autoimmune POF is important for early conception and oocyte preservation, because the only other option at present is ovum donation.
- | purified human menopausal gonadotropin / Generic mfg.
Journal: Phosphorylation of MtRopGEF2 by LYK3 mediates MtROP activity to regulate rhizobial infection in Medicago truncatula. (Pubmed Central) - Feb 4, 2022
Activated MtRac1 was found to localize at the tips of root hairs and to strongly interact with LYK3 and NFP. Taken together, our results support the hypothesis that MtRac1, LYK3, and NFP form a polarly localized receptor complex that regulates root hair deformation during rhizobial infection.
- || Menopur (menotropin) / Ferring
Clinical, Observational data, Journal, HEOR: Comparative effectiveness of recombinant human follicle-stimulating hormone alfa (r-hFSH-alfa) versus highly purified urinary human menopausal gonadotropin (hMG HP) in assisted reproductive technology (ART) treatments: a non-interventional study in Germany. (Pubmed Central) - Dec 16, 2021
Taken together, our results support the hypothesis that MtRac1, LYK3, and NFP form a polarly localized receptor complex that regulates root hair deformation during rhizobial infection. This large (> 28,000 women), real-world study demonstrated significantly higher rates of cumulative live birth, cumulative ongoing pregnancy and cumulative clinical pregnancy with r-hFSH-alfa versus hMG HP.
- | Menopur (menotropin) / Ferring
Journal: First pre-filled pen device with highly purified human menopausal gonadotropin (HP-hMG, Menopur) in liquid is shown to be bioequivalent to powder for reconstitution. (Pubmed Central) - Nov 21, 2021
This large (> 28,000 women), real-world study demonstrated significantly higher rates of cumulative live birth, cumulative ongoing pregnancy and cumulative clinical pregnancy with r-hFSH-alfa versus hMG HP. The 90% CIs for the geometric mean ratios of serum FSH AUC and C were both within 0.8000 - 1.2500, thus the two formulations are bioequivalent.
- | Rekovelle (follitropin delta) / Ferring
Preclinical, Journal: Individualized ovarian stimulation for in vitro fertilization: a multicenter, open label, exploratory study with a mixed protocol of follitropin delta and highly purified human menopausal gonadotropin. (Pubmed Central) - Aug 4, 2021
P=N/A
The 90% CIs for the geometric mean ratios of serum FSH AUC and C were both within 0.8000 - 1.2500, thus the two formulations are bioequivalent. Optimizing the ovarian response during in vitro fertilization employing a mixed protocol of individualized dosing of follitropin delta and HP-hMG resulted in a statistically significant number of usable blastocysts on days 5 and 6 with an increased risk of mild OHSS, which did not require medical intervention or hospitalization.
- || purified human menopausal gonadotropin / Generic mfg., menotropin / Generic mfg.
Clinical, Journal: Early pregnancy loss in patients with polycystic ovary syndrome after IVM versus standard ovarian stimulation for IVF/ICSI. (Pubmed Central) - May 5, 2021
All authors declared no conflict of interest. N/A.
- | purified human menopausal gonadotropin / Generic mfg.
Journal: The Effect of Lockdown Period during the COVID-19 Pandemic on Air Quality in Sydney Region, Australia. (Pubmed Central) - Apr 14, 2021
The results from both statistical and modelling methods show that NO, CO, and PM levels decreased during the lockdown, but O instead increased. However, the change in the concentration levels are small considering the large reduction of ~30% in traffic volume.
- | Rekovelle (follitropin delta) / Ferring, Menopur (menotropin) / Ferring
Trial completion, Preclinical: MARCS: Menopur And Rekovelle Combination Study (clinicaltrials.gov) - Aug 28, 2019
P=N/A, N=160, Completed, Sponsor: Dr François Bissonnette
However, the change in the concentration levels are small considering the large reduction of ~30% in traffic volume. Recruiting --> Completed
- | Rekovelle (follitropin delta) / Ferring, Menopur (menotropin) / Ferring
Preclinical, Trial completion date, Trial primary completion date: MARCS: Menopur And Rekovelle Combination Study (clinicaltrials.gov) - Jan 31, 2019
P=N/A, N=160, Recruiting, Sponsor: Dr François Bissonnette
Recruiting --> Completed Trial completion date: Dec 2018 --> May 2019 | Trial primary completion date: Dec 2018 --> May 2019
- | Rekovelle (follitropin delta) / Ferring, Menopur (menotropin) / Ferring
Enrollment open, Preclinical, Trial completion date, Trial primary completion date: MARCS: Menopur And Rekovelle Combination Study (clinicaltrials.gov) - Oct 1, 2018
P=N/A, N=160, Recruiting, Sponsor: Dr François Bissonnette
Trial completion date: Dec 2018 --> May 2019 | Trial primary completion date: Dec 2018 --> May 2019 Not yet recruiting --> Recruiting | Trial completion date: Sep 2018 --> Dec 2018 | Trial primary completion date: Aug 2018 --> Dec 2018
- | Rekovelle (follitropin delta) / Ferring, Menopur (menotropin) / Ferring
Preclinical, Trial initiation date: MARCS: Menopur And Rekovelle Combination Study (clinicaltrials.gov) - Jul 16, 2018
P=N/A, N=160, Not yet recruiting, Sponsor: Dr François Bissonnette
Not yet recruiting --> Recruiting | Trial completion date: Sep 2018 --> Dec 2018 | Trial primary completion date: Aug 2018 --> Dec 2018 Initiation date: May 2018 --> Aug 2018
- | Rekovelle (follitropin delta) / Ferring, Menopur (menotropin) / Ferring
New trial, Preclinical: MARCS: Menopur And Rekovelle Combination Study (clinicaltrials.gov) - Mar 31, 2018
P=N/A, N=160, Not yet recruiting, Sponsor: Dr François Bissonnette
- | purified human menopausal gonadotropin / Generic mfg.
New P4 trial: Androgenic Profile Following Controlled Ovarian Stimulation (clinicaltrials.gov) - Dec 14, 2016
P4, N=100, Not yet recruiting, Sponsor: Sheba Medical Center